Avestar Capital LLC Trims Stake in InspireMD, Inc. (NYSE:NSPR)

Avestar Capital LLC reduced its position in shares of InspireMD, Inc. (NYSE:NSPR) by 25.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,000 shares of the company’s stock after selling 5,000 shares during the period. Avestar Capital LLC’s holdings in InspireMD were worth $40,000 at the end of the most recent quarter.

Separately, Affiance Financial LLC purchased a new position in InspireMD in the third quarter worth $492,000. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. StockNews.com assumed coverage on shares of InspireMD in a research report on Tuesday. They issued a “sell” rating for the company. Piper Sandler reiterated an “overweight” rating and issued a $4.50 target price on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Stock Down 3.3 %

NYSE NSPR opened at $2.92 on Friday. The company has a 50-day simple moving average of $2.59 and a two-hundred day simple moving average of $2.63. InspireMD, Inc. has a 12-month low of $1.81 and a 12-month high of $3.42. The firm has a market cap of $76.15 million, a price-to-earnings ratio of -3.89 and a beta of 0.93.

InspireMD (NYSE:NSPR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. The business had revenue of $1.81 million during the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same period in the prior year, the business posted ($0.15) earnings per share. Equities analysts expect that InspireMD, Inc. will post -0.79 earnings per share for the current fiscal year.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.